Cabaletta Bio Extends Cash Runway Into 1Q 28
Cabaletta Bio reported a cash position of $299.4 million as of Sept. 30 and an operational runway extending into 1Q 28.
Related stories
Palvella Therapeutics Posts Q3 Loss of $1.70 a Share
M impact | EQUITY | Nov 05, 2026, 12:59 PM UTC
Howdens reports group sales up 6.8%, reaffirms outlook
The kitchen and joinery supplier said group sales rose 6.8% in the period from 14 June to 31 October. On a pro-forma basis, group sales increased 2.1%, with domestic sales up 1.8%;
M impact | EQUITY | Nov 05, 2026, 12:46 PM UTC
Berenberg Raises Helios Towers Target After Q3 Tenancy Beat
Berenberg said Helios Towers added 924 tenancies in the third quarter, lifting its total to 35,379, up 12.2% year on year and above consensus. The headline also cites a boost to FY
L impact | EQUITY | Nov 05, 2026, 12:46 PM UTC
Lundin Mining Q3 Adjusted Earnings Climb Year Over Year
Lundin Mining reported Q3 adjusted earnings of $0.
M impact | EQUITY | Nov 05, 2026, 12:46 PM UTC
Zoetis Reports Higher Q3 Adjusted Earnings, Lower Revenue; Lifts 2026 Guidance
Zoetis reported Q3 adjusted earnings of $1, while revenue declined. The company lifted its 2026 guidance.
M impact | EQUITY | Nov 05, 2026, 12:46 PM UTC
Cummins Q3 Profit Beats on Strong Data Center Demand
M impact | EQUITY | Nov 05, 2026, 12:46 PM UTC